ALFA Finder| Management target | Revenue 18.0% FY27 |
|---|
| Revenue growth | 26.4% YoY, driven by center maturation and network expansion. |
|---|---|
| Margins | EBITDA margin rose to 36.7%; targets 34-35% steady state next year. |
| Demand visibility | Strong visibility in genomics and specialized diagnostics; seasonal Q3 dip noted. |
| Management confidence | Confident and disciplined; focusing on cluster-building and operational leverage. |
Growth
Revenue grew 26.4% YoY; EBITDA margins expanded to 36.7% due to maturing centers.
Outlook
Management guides for 15-18% revenue growth for FY27 with steady 34-35% EBITDA margins.
Risks
Seasonal festive headwinds in Q3; execution risks in new geographies like Jharkhand and Tripura.
Last quarter's promises, checked
Delivered
- Guided EBITDA margin not below 34% for FY27 → delivered 36.7% (= BEAT)
- Guided ~20% quarterly revenue growth → delivered 26.4% YoY (= BEAT)
- Guided sub-2yr centre margin improvement from 6.5% → delivered 11.8% (= BEAT)
Partly delivered
- Guided Tripura hub 'will follow shortly' → now 'operations starting H2' (= PARTIAL)
Earnings Call Transcript filed with NSE, NSE: SURAKSHA. Summary written with AI assistance from the document.
Suraksha Diagnostic Ltd: key numbers
- Share price
- ₹347.70
- Market cap
- ₹1,811 Cr
- Revenue (annual)
- ₹310.4 Cr
- Net profit (annual)
- ₹32.19 Cr
- P/E (TTM)
- 43.3×Sector 54.7×
- Promoter holding
- 49.10%+0.00% QoQ
- FII holding
- 13.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Suraksha Diagnostic Ltd
All →Suraksha Diagnostic Investor Presentation: Key Takeaways
Q2 FY27 total income INR 1,006 Mn (+26% YoY), EBITDA INR 363 Mn (36.7% margin), PAT INR 149.5 Mn (+69%). H1 PAT INR 278 Mn (+54%). Growth driven by network expansion and maturing centres.
Suraksha Diagnostic Results Correction
Suraksha Diagnostic corrected operational metrics in its 10 November 2026 results press release. Test volumes and revenue per test were revised; financial figures are unchanged.
Suraksha Diagnostic Results Update
Suraksha Diagnostic reported H1 FY27 total income of ₹1,893.09 million and PAT of ₹277.96 million, up 54% year-on-year. The press release accompanies its unaudited quarterly results.
Suraksha Diagnostic Q2 FY27 Results: Net Profit ₹15 Cr, Up 70.5% YoY
Suraksha Diagnostic Ltd reported revenue from operations of ₹99.1 Cr (+25.9% YoY) and net profit of ₹15 Cr (+70.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹15 Cr · +70.5% YoY
Suraksha Diagnostic Board Meeting Date
Suraksha Diagnostic will hold a board meeting on 10 November 2026 to consider September quarter results and other business. Trading window closes from 1 October to 12 November 2026.
Suraksha Diagnostic Other Announcement
Suraksha Diagnostic notified that RTA KFin Technologies is moving its corporate office to Kokapet, Hyderabad from 1 December 2026, with the registered office unchanged. The change is administrative and affects only the RTA's correspondence address.